Pharma & Healthcare
Global Necrotizing Autoimmune Myositis Market Research Report 2025
- Mar 11, 25
- ID: 29508
- Pages: 80
- Figures: 79
- Views: 16
The global market for Necrotizing Autoimmune Myositis was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Necrotizing Autoimmune Myositis is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Necrotizing Autoimmune Myositis is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Necrotizing Autoimmune Myositis in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Necrotizing Autoimmune Myositis include GlaxoSmithKline plc, Dr. Reddy's Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries, Novartis AG, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Necrotizing Autoimmune Myositis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Necrotizing Autoimmune Myositis.
The Necrotizing Autoimmune Myositis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Necrotizing Autoimmune Myositis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Necrotizing Autoimmune Myositis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline plc
Dr. Reddy's Laboratories
Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
Hetero Drugs Limited
AbbVie Inc.
Teva Pharmaceutical Industries
Novartis AG
Segment by Type
Steroid Drugs
Immunosuppressant
Others
Segment by Application
Hospital
Pharmacy
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Necrotizing Autoimmune Myositis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Necrotizing Autoimmune Myositis is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Necrotizing Autoimmune Myositis is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Necrotizing Autoimmune Myositis in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Necrotizing Autoimmune Myositis include GlaxoSmithKline plc, Dr. Reddy's Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries, Novartis AG, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Necrotizing Autoimmune Myositis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Necrotizing Autoimmune Myositis.
The Necrotizing Autoimmune Myositis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Necrotizing Autoimmune Myositis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Necrotizing Autoimmune Myositis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline plc
Dr. Reddy's Laboratories
Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
Hetero Drugs Limited
AbbVie Inc.
Teva Pharmaceutical Industries
Novartis AG
Segment by Type
Steroid Drugs
Immunosuppressant
Others
Segment by Application
Hospital
Pharmacy
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Necrotizing Autoimmune Myositis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Necrotizing Autoimmune Myositis Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Steroid Drugs
1.2.3 Immunosuppressant
1.2.4 Others
1.3 Market by Application
1.3.1 Global Necrotizing Autoimmune Myositis Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Necrotizing Autoimmune Myositis Market Perspective (2020-2031)
2.2 Global Necrotizing Autoimmune Myositis Growth Trends by Region
2.2.1 Global Necrotizing Autoimmune Myositis Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Necrotizing Autoimmune Myositis Historic Market Size by Region (2020-2025)
2.2.3 Necrotizing Autoimmune Myositis Forecasted Market Size by Region (2026-2031)
2.3 Necrotizing Autoimmune Myositis Market Dynamics
2.3.1 Necrotizing Autoimmune Myositis Industry Trends
2.3.2 Necrotizing Autoimmune Myositis Market Drivers
2.3.3 Necrotizing Autoimmune Myositis Market Challenges
2.3.4 Necrotizing Autoimmune Myositis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Necrotizing Autoimmune Myositis Players by Revenue
3.1.1 Global Top Necrotizing Autoimmune Myositis Players by Revenue (2020-2025)
3.1.2 Global Necrotizing Autoimmune Myositis Revenue Market Share by Players (2020-2025)
3.2 Global Necrotizing Autoimmune Myositis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Necrotizing Autoimmune Myositis Revenue
3.4 Global Necrotizing Autoimmune Myositis Market Concentration Ratio
3.4.1 Global Necrotizing Autoimmune Myositis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Necrotizing Autoimmune Myositis Revenue in 2024
3.5 Global Key Players of Necrotizing Autoimmune Myositis Head office and Area Served
3.6 Global Key Players of Necrotizing Autoimmune Myositis, Product and Application
3.7 Global Key Players of Necrotizing Autoimmune Myositis, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Necrotizing Autoimmune Myositis Breakdown Data by Type
4.1 Global Necrotizing Autoimmune Myositis Historic Market Size by Type (2020-2025)
4.2 Global Necrotizing Autoimmune Myositis Forecasted Market Size by Type (2026-2031)
5 Necrotizing Autoimmune Myositis Breakdown Data by Application
5.1 Global Necrotizing Autoimmune Myositis Historic Market Size by Application (2020-2025)
5.2 Global Necrotizing Autoimmune Myositis Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Necrotizing Autoimmune Myositis Market Size (2020-2031)
6.2 North America Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
6.4 North America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Necrotizing Autoimmune Myositis Market Size (2020-2031)
7.2 Europe Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
7.4 Europe Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Necrotizing Autoimmune Myositis Market Size (2020-2031)
8.2 Asia-Pacific Necrotizing Autoimmune Myositis Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2020-2025)
8.4 Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Necrotizing Autoimmune Myositis Market Size (2020-2031)
9.2 Latin America Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
9.4 Latin America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Necrotizing Autoimmune Myositis Market Size (2020-2031)
10.2 Middle East & Africa Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
10.4 Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline plc
11.1.1 GlaxoSmithKline plc Company Details
11.1.2 GlaxoSmithKline plc Business Overview
11.1.3 GlaxoSmithKline plc Necrotizing Autoimmune Myositis Introduction
11.1.4 GlaxoSmithKline plc Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.1.5 GlaxoSmithKline plc Recent Development
11.2 Dr. Reddy's Laboratories
11.2.1 Dr. Reddy's Laboratories Company Details
11.2.2 Dr. Reddy's Laboratories Business Overview
11.2.3 Dr. Reddy's Laboratories Necrotizing Autoimmune Myositis Introduction
11.2.4 Dr. Reddy's Laboratories Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.2.5 Dr. Reddy's Laboratories Recent Development
11.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
11.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Details
11.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Business Overview
11.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Introduction
11.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Development
11.4 Hetero Drugs Limited
11.4.1 Hetero Drugs Limited Company Details
11.4.2 Hetero Drugs Limited Business Overview
11.4.3 Hetero Drugs Limited Necrotizing Autoimmune Myositis Introduction
11.4.4 Hetero Drugs Limited Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.4.5 Hetero Drugs Limited Recent Development
11.5 AbbVie Inc.
11.5.1 AbbVie Inc. Company Details
11.5.2 AbbVie Inc. Business Overview
11.5.3 AbbVie Inc. Necrotizing Autoimmune Myositis Introduction
11.5.4 AbbVie Inc. Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.5.5 AbbVie Inc. Recent Development
11.6 Teva Pharmaceutical Industries
11.6.1 Teva Pharmaceutical Industries Company Details
11.6.2 Teva Pharmaceutical Industries Business Overview
11.6.3 Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Introduction
11.6.4 Teva Pharmaceutical Industries Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.6.5 Teva Pharmaceutical Industries Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Necrotizing Autoimmune Myositis Introduction
11.7.4 Novartis AG Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.7.5 Novartis AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Necrotizing Autoimmune Myositis Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Steroid Drugs
1.2.3 Immunosuppressant
1.2.4 Others
1.3 Market by Application
1.3.1 Global Necrotizing Autoimmune Myositis Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Necrotizing Autoimmune Myositis Market Perspective (2020-2031)
2.2 Global Necrotizing Autoimmune Myositis Growth Trends by Region
2.2.1 Global Necrotizing Autoimmune Myositis Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Necrotizing Autoimmune Myositis Historic Market Size by Region (2020-2025)
2.2.3 Necrotizing Autoimmune Myositis Forecasted Market Size by Region (2026-2031)
2.3 Necrotizing Autoimmune Myositis Market Dynamics
2.3.1 Necrotizing Autoimmune Myositis Industry Trends
2.3.2 Necrotizing Autoimmune Myositis Market Drivers
2.3.3 Necrotizing Autoimmune Myositis Market Challenges
2.3.4 Necrotizing Autoimmune Myositis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Necrotizing Autoimmune Myositis Players by Revenue
3.1.1 Global Top Necrotizing Autoimmune Myositis Players by Revenue (2020-2025)
3.1.2 Global Necrotizing Autoimmune Myositis Revenue Market Share by Players (2020-2025)
3.2 Global Necrotizing Autoimmune Myositis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Necrotizing Autoimmune Myositis Revenue
3.4 Global Necrotizing Autoimmune Myositis Market Concentration Ratio
3.4.1 Global Necrotizing Autoimmune Myositis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Necrotizing Autoimmune Myositis Revenue in 2024
3.5 Global Key Players of Necrotizing Autoimmune Myositis Head office and Area Served
3.6 Global Key Players of Necrotizing Autoimmune Myositis, Product and Application
3.7 Global Key Players of Necrotizing Autoimmune Myositis, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Necrotizing Autoimmune Myositis Breakdown Data by Type
4.1 Global Necrotizing Autoimmune Myositis Historic Market Size by Type (2020-2025)
4.2 Global Necrotizing Autoimmune Myositis Forecasted Market Size by Type (2026-2031)
5 Necrotizing Autoimmune Myositis Breakdown Data by Application
5.1 Global Necrotizing Autoimmune Myositis Historic Market Size by Application (2020-2025)
5.2 Global Necrotizing Autoimmune Myositis Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Necrotizing Autoimmune Myositis Market Size (2020-2031)
6.2 North America Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
6.4 North America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Necrotizing Autoimmune Myositis Market Size (2020-2031)
7.2 Europe Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
7.4 Europe Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Necrotizing Autoimmune Myositis Market Size (2020-2031)
8.2 Asia-Pacific Necrotizing Autoimmune Myositis Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2020-2025)
8.4 Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Necrotizing Autoimmune Myositis Market Size (2020-2031)
9.2 Latin America Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
9.4 Latin America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Necrotizing Autoimmune Myositis Market Size (2020-2031)
10.2 Middle East & Africa Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
10.4 Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline plc
11.1.1 GlaxoSmithKline plc Company Details
11.1.2 GlaxoSmithKline plc Business Overview
11.1.3 GlaxoSmithKline plc Necrotizing Autoimmune Myositis Introduction
11.1.4 GlaxoSmithKline plc Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.1.5 GlaxoSmithKline plc Recent Development
11.2 Dr. Reddy's Laboratories
11.2.1 Dr. Reddy's Laboratories Company Details
11.2.2 Dr. Reddy's Laboratories Business Overview
11.2.3 Dr. Reddy's Laboratories Necrotizing Autoimmune Myositis Introduction
11.2.4 Dr. Reddy's Laboratories Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.2.5 Dr. Reddy's Laboratories Recent Development
11.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
11.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Details
11.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Business Overview
11.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Introduction
11.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Development
11.4 Hetero Drugs Limited
11.4.1 Hetero Drugs Limited Company Details
11.4.2 Hetero Drugs Limited Business Overview
11.4.3 Hetero Drugs Limited Necrotizing Autoimmune Myositis Introduction
11.4.4 Hetero Drugs Limited Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.4.5 Hetero Drugs Limited Recent Development
11.5 AbbVie Inc.
11.5.1 AbbVie Inc. Company Details
11.5.2 AbbVie Inc. Business Overview
11.5.3 AbbVie Inc. Necrotizing Autoimmune Myositis Introduction
11.5.4 AbbVie Inc. Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.5.5 AbbVie Inc. Recent Development
11.6 Teva Pharmaceutical Industries
11.6.1 Teva Pharmaceutical Industries Company Details
11.6.2 Teva Pharmaceutical Industries Business Overview
11.6.3 Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Introduction
11.6.4 Teva Pharmaceutical Industries Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.6.5 Teva Pharmaceutical Industries Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Necrotizing Autoimmune Myositis Introduction
11.7.4 Novartis AG Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.7.5 Novartis AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Necrotizing Autoimmune Myositis Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Steroid Drugs
Table 3. Key Players of Immunosuppressant
Table 4. Key Players of Others
Table 5. Global Necrotizing Autoimmune Myositis Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Necrotizing Autoimmune Myositis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Necrotizing Autoimmune Myositis Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Necrotizing Autoimmune Myositis Market Share by Region (2020-2025)
Table 9. Global Necrotizing Autoimmune Myositis Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Necrotizing Autoimmune Myositis Market Share by Region (2026-2031)
Table 11. Necrotizing Autoimmune Myositis Market Trends
Table 12. Necrotizing Autoimmune Myositis Market Drivers
Table 13. Necrotizing Autoimmune Myositis Market Challenges
Table 14. Necrotizing Autoimmune Myositis Market Restraints
Table 15. Global Necrotizing Autoimmune Myositis Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Necrotizing Autoimmune Myositis Market Share by Players (2020-2025)
Table 17. Global Top Necrotizing Autoimmune Myositis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Necrotizing Autoimmune Myositis as of 2024)
Table 18. Ranking of Global Top Necrotizing Autoimmune Myositis Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Necrotizing Autoimmune Myositis Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Necrotizing Autoimmune Myositis, Headquarters and Area Served
Table 21. Global Key Players of Necrotizing Autoimmune Myositis, Product and Application
Table 22. Global Key Players of Necrotizing Autoimmune Myositis, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Necrotizing Autoimmune Myositis Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Necrotizing Autoimmune Myositis Revenue Market Share by Type (2020-2025)
Table 26. Global Necrotizing Autoimmune Myositis Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Necrotizing Autoimmune Myositis Revenue Market Share by Type (2026-2031)
Table 28. Global Necrotizing Autoimmune Myositis Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Necrotizing Autoimmune Myositis Revenue Market Share by Application (2020-2025)
Table 30. Global Necrotizing Autoimmune Myositis Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Necrotizing Autoimmune Myositis Revenue Market Share by Application (2026-2031)
Table 32. North America Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Necrotizing Autoimmune Myositis Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 47. GlaxoSmithKline plc Company Details
Table 48. GlaxoSmithKline plc Business Overview
Table 49. GlaxoSmithKline plc Necrotizing Autoimmune Myositis Product
Table 50. GlaxoSmithKline plc Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 51. GlaxoSmithKline plc Recent Development
Table 52. Dr. Reddy's Laboratories Company Details
Table 53. Dr. Reddy's Laboratories Business Overview
Table 54. Dr. Reddy's Laboratories Necrotizing Autoimmune Myositis Product
Table 55. Dr. Reddy's Laboratories Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 56. Dr. Reddy's Laboratories Recent Development
Table 57. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Details
Table 58. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Business Overview
Table 59. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Product
Table 60. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 61. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Development
Table 62. Hetero Drugs Limited Company Details
Table 63. Hetero Drugs Limited Business Overview
Table 64. Hetero Drugs Limited Necrotizing Autoimmune Myositis Product
Table 65. Hetero Drugs Limited Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 66. Hetero Drugs Limited Recent Development
Table 67. AbbVie Inc. Company Details
Table 68. AbbVie Inc. Business Overview
Table 69. AbbVie Inc. Necrotizing Autoimmune Myositis Product
Table 70. AbbVie Inc. Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 71. AbbVie Inc. Recent Development
Table 72. Teva Pharmaceutical Industries Company Details
Table 73. Teva Pharmaceutical Industries Business Overview
Table 74. Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Product
Table 75. Teva Pharmaceutical Industries Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 76. Teva Pharmaceutical Industries Recent Development
Table 77. Novartis AG Company Details
Table 78. Novartis AG Business Overview
Table 79. Novartis AG Necrotizing Autoimmune Myositis Product
Table 80. Novartis AG Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 81. Novartis AG Recent Development
Table 82. Research Programs/Design for This Report
Table 83. Key Data Information from Secondary Sources
Table 84. Key Data Information from Primary Sources
Table 85. Authors List of This Report
List of Figures
Figure 1. Necrotizing Autoimmune Myositis Picture
Figure 2. Global Necrotizing Autoimmune Myositis Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Necrotizing Autoimmune Myositis Market Share by Type: 2024 VS 2031
Figure 4. Steroid Drugs Features
Figure 5. Immunosuppressant Features
Figure 6. Others Features
Figure 7. Global Necrotizing Autoimmune Myositis Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Necrotizing Autoimmune Myositis Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Pharmacy Case Studies
Figure 11. Others Case Studies
Figure 12. Necrotizing Autoimmune Myositis Report Years Considered
Figure 13. Global Necrotizing Autoimmune Myositis Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Necrotizing Autoimmune Myositis Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Necrotizing Autoimmune Myositis Market Share by Region: 2024 VS 2031
Figure 16. Global Necrotizing Autoimmune Myositis Market Share by Players in 2024
Figure 17. Global Top Necrotizing Autoimmune Myositis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Necrotizing Autoimmune Myositis as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Necrotizing Autoimmune Myositis Revenue in 2024
Figure 19. North America Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 21. United States Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 25. Germany Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Necrotizing Autoimmune Myositis Market Share by Region (2020-2031)
Figure 33. China Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 41. Mexico Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 45. Turkey Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. GlaxoSmithKline plc Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 49. Dr. Reddy's Laboratories Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 50. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 51. Hetero Drugs Limited Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 52. AbbVie Inc. Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 53. Teva Pharmaceutical Industries Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 54. Novartis AG Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Table 1. Global Necrotizing Autoimmune Myositis Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Steroid Drugs
Table 3. Key Players of Immunosuppressant
Table 4. Key Players of Others
Table 5. Global Necrotizing Autoimmune Myositis Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Necrotizing Autoimmune Myositis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Necrotizing Autoimmune Myositis Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Necrotizing Autoimmune Myositis Market Share by Region (2020-2025)
Table 9. Global Necrotizing Autoimmune Myositis Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Necrotizing Autoimmune Myositis Market Share by Region (2026-2031)
Table 11. Necrotizing Autoimmune Myositis Market Trends
Table 12. Necrotizing Autoimmune Myositis Market Drivers
Table 13. Necrotizing Autoimmune Myositis Market Challenges
Table 14. Necrotizing Autoimmune Myositis Market Restraints
Table 15. Global Necrotizing Autoimmune Myositis Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Necrotizing Autoimmune Myositis Market Share by Players (2020-2025)
Table 17. Global Top Necrotizing Autoimmune Myositis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Necrotizing Autoimmune Myositis as of 2024)
Table 18. Ranking of Global Top Necrotizing Autoimmune Myositis Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Necrotizing Autoimmune Myositis Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Necrotizing Autoimmune Myositis, Headquarters and Area Served
Table 21. Global Key Players of Necrotizing Autoimmune Myositis, Product and Application
Table 22. Global Key Players of Necrotizing Autoimmune Myositis, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Necrotizing Autoimmune Myositis Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Necrotizing Autoimmune Myositis Revenue Market Share by Type (2020-2025)
Table 26. Global Necrotizing Autoimmune Myositis Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Necrotizing Autoimmune Myositis Revenue Market Share by Type (2026-2031)
Table 28. Global Necrotizing Autoimmune Myositis Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Necrotizing Autoimmune Myositis Revenue Market Share by Application (2020-2025)
Table 30. Global Necrotizing Autoimmune Myositis Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Necrotizing Autoimmune Myositis Revenue Market Share by Application (2026-2031)
Table 32. North America Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Necrotizing Autoimmune Myositis Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 47. GlaxoSmithKline plc Company Details
Table 48. GlaxoSmithKline plc Business Overview
Table 49. GlaxoSmithKline plc Necrotizing Autoimmune Myositis Product
Table 50. GlaxoSmithKline plc Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 51. GlaxoSmithKline plc Recent Development
Table 52. Dr. Reddy's Laboratories Company Details
Table 53. Dr. Reddy's Laboratories Business Overview
Table 54. Dr. Reddy's Laboratories Necrotizing Autoimmune Myositis Product
Table 55. Dr. Reddy's Laboratories Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 56. Dr. Reddy's Laboratories Recent Development
Table 57. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Details
Table 58. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Business Overview
Table 59. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Product
Table 60. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 61. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Development
Table 62. Hetero Drugs Limited Company Details
Table 63. Hetero Drugs Limited Business Overview
Table 64. Hetero Drugs Limited Necrotizing Autoimmune Myositis Product
Table 65. Hetero Drugs Limited Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 66. Hetero Drugs Limited Recent Development
Table 67. AbbVie Inc. Company Details
Table 68. AbbVie Inc. Business Overview
Table 69. AbbVie Inc. Necrotizing Autoimmune Myositis Product
Table 70. AbbVie Inc. Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 71. AbbVie Inc. Recent Development
Table 72. Teva Pharmaceutical Industries Company Details
Table 73. Teva Pharmaceutical Industries Business Overview
Table 74. Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Product
Table 75. Teva Pharmaceutical Industries Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 76. Teva Pharmaceutical Industries Recent Development
Table 77. Novartis AG Company Details
Table 78. Novartis AG Business Overview
Table 79. Novartis AG Necrotizing Autoimmune Myositis Product
Table 80. Novartis AG Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 81. Novartis AG Recent Development
Table 82. Research Programs/Design for This Report
Table 83. Key Data Information from Secondary Sources
Table 84. Key Data Information from Primary Sources
Table 85. Authors List of This Report
List of Figures
Figure 1. Necrotizing Autoimmune Myositis Picture
Figure 2. Global Necrotizing Autoimmune Myositis Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Necrotizing Autoimmune Myositis Market Share by Type: 2024 VS 2031
Figure 4. Steroid Drugs Features
Figure 5. Immunosuppressant Features
Figure 6. Others Features
Figure 7. Global Necrotizing Autoimmune Myositis Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Necrotizing Autoimmune Myositis Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Pharmacy Case Studies
Figure 11. Others Case Studies
Figure 12. Necrotizing Autoimmune Myositis Report Years Considered
Figure 13. Global Necrotizing Autoimmune Myositis Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Necrotizing Autoimmune Myositis Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Necrotizing Autoimmune Myositis Market Share by Region: 2024 VS 2031
Figure 16. Global Necrotizing Autoimmune Myositis Market Share by Players in 2024
Figure 17. Global Top Necrotizing Autoimmune Myositis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Necrotizing Autoimmune Myositis as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Necrotizing Autoimmune Myositis Revenue in 2024
Figure 19. North America Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 21. United States Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 25. Germany Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Necrotizing Autoimmune Myositis Market Share by Region (2020-2031)
Figure 33. China Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 41. Mexico Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 45. Turkey Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. GlaxoSmithKline plc Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 49. Dr. Reddy's Laboratories Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 50. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 51. Hetero Drugs Limited Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 52. AbbVie Inc. Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 53. Teva Pharmaceutical Industries Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 54. Novartis AG Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232